The study focuses on adults diagnosed with Major Depressive Disorder, a condition that causes a deep, lasting sadness, loss of interest in usual activities, and problems with sleep, appetite, and concentration. The medication being tested is named azetukalner and is taken as a small capsule by mouth once each day.
The purpose of the trial is to find out if long‑term treatment with azetukalner is safe and can be tolerated without serious side effects. Participants will attend regular clinic visits where they will have basic health checks, give blood samples, and complete short questionnaires about how they feel. The study will continue for many months so researchers can observe any issues that might develop over time.
Besides safety, the study will track changes in mood and daily functioning using several common rating tools: the HAMD-17 score, which is a list of questions that measures how severe the depression is; the SHAPS score, which looks at the ability to feel pleasure; the CGI-S rating, a doctor’s overall impression of illness severity; the Q-LES-Q-SF survey, which asks about enjoyment of everyday life; and the SDS questionnaire, which checks how depression affects work, social activities, and home tasks. These measures help determine whether the medication improves or worsens the condition.
Finland 
Poland 
Romania 
Slovakia 
Spain 
